(Total Views: 497)
Posted On: 02/09/2025 4:22:49 PM
Post# of 150038
Yes, I still am grappling with everything contained in the December Letter to Shareholders, and occasionally re-read it again when I need a little lift. Lol!
Here’s a bit concerning the third study in mice to confirm LL monotherapy and our ability to reverse “established fibrosis”.
First, from the PR last week re: 3rd study…as opposed to the first two studies held in 2024 in which a high fat diet and a dose of Streptozocin caused the liver fibrosis, similarly to fatty liver, Mash…not other etiologies such as Chirrosis or viral hepatitis.
“The third study, concluded in January 2025, evaluated reversal of liver fibrosis in mice who received carbon tetrachloride, a liver fibrosis-inducing agent, from birth to sacrifice at day 35.”
And now from shareholders letter…CCL4 = Carbon Tetrachloride…
“The second follow-up study involves the administration of CCL4, a drug that directly causes liver fibrosis in mice. This study will clarify if the observed reversal of liver fibrosis is restricted to the MASH/fat deposition pathway or might occur independently of the etiology of fibrosis (e.g. alcohol, viral hepatitis, etc.). The results from both follow-up studies will become available in January. As a side note, we have been contacted by colleagues at a major academic institution who indicated that, if the liver fibrosis reversal results are confirmed in the follow-up studies, they would be interested in funding a pilot study of leronlimab in the treatment of patients with pulmonary fibrosis at their own center.”
And this is why you work with the best CRO in liver disease, SMC. We’ve confirmed directly reversal in mice livers, no matter the cause.
Well…if that holds true in cardio pulmonary indications? Damn…I’ll wish I owned more shares.
PS…for good measure from letter…
“Third, we have finalized the protocol for a pilot study of leronlimab in the treatment of patients with mild to moderate Alzheimer’s disease. That study will take place at Cornell Medical Center in New York and will evaluate an objective neuroradiology primary endpoint that will provide a clear measure of leronlimab’s potential role in treating Alzheimer’s disease. I am pleased to announce the study is now fully funded by an outside foundation, and the protocol will soon be submitted to both the FDA and the Cornell IRB.”
Here’s a bit concerning the third study in mice to confirm LL monotherapy and our ability to reverse “established fibrosis”.
First, from the PR last week re: 3rd study…as opposed to the first two studies held in 2024 in which a high fat diet and a dose of Streptozocin caused the liver fibrosis, similarly to fatty liver, Mash…not other etiologies such as Chirrosis or viral hepatitis.
“The third study, concluded in January 2025, evaluated reversal of liver fibrosis in mice who received carbon tetrachloride, a liver fibrosis-inducing agent, from birth to sacrifice at day 35.”
And now from shareholders letter…CCL4 = Carbon Tetrachloride…
“The second follow-up study involves the administration of CCL4, a drug that directly causes liver fibrosis in mice. This study will clarify if the observed reversal of liver fibrosis is restricted to the MASH/fat deposition pathway or might occur independently of the etiology of fibrosis (e.g. alcohol, viral hepatitis, etc.). The results from both follow-up studies will become available in January. As a side note, we have been contacted by colleagues at a major academic institution who indicated that, if the liver fibrosis reversal results are confirmed in the follow-up studies, they would be interested in funding a pilot study of leronlimab in the treatment of patients with pulmonary fibrosis at their own center.”
And this is why you work with the best CRO in liver disease, SMC. We’ve confirmed directly reversal in mice livers, no matter the cause.
Well…if that holds true in cardio pulmonary indications? Damn…I’ll wish I owned more shares.
PS…for good measure from letter…
“Third, we have finalized the protocol for a pilot study of leronlimab in the treatment of patients with mild to moderate Alzheimer’s disease. That study will take place at Cornell Medical Center in New York and will evaluate an objective neuroradiology primary endpoint that will provide a clear measure of leronlimab’s potential role in treating Alzheimer’s disease. I am pleased to announce the study is now fully funded by an outside foundation, and the protocol will soon be submitted to both the FDA and the Cornell IRB.”
(22)
(0)Scroll down for more posts ▼
